Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael D Ezekowitz

Showing results (81-90 of 187) with videos related to

Pageof 19
Sort By:
Circulation|October 2, 2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarinAmmar Majeed, Hun-Gyu Hwang, Stuart J Connolly, et al.
International Journal of Cardiology. Heart & Vasculature|October 17, 2022
Retrospective Comparison of Patients ≥ 80 Years With Atrial Fibrillation Prescribed Either an FDA-Approved Reduced or Full Dose Direct-Acting Oral AnticoagulantRoy Taoutel, Michael D Ezekowitz, Usman A Chaudhry, et al.
Circulation|August 7, 2016
Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy)Michael D Ezekowitz, Rangadham Nagarakanti, Herbert Noack, et al.
American Heart Journal|April 15, 2018
Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysisZiad Hijazi, Stefan H Hohnloser, Jonas Oldgren, et al.
Cardiovascular Pathology : the Official Journal of the Society for Cardiovascular Pathology|April 12, 2008
Identification of tissue factor in experimental aortic valve sclerosisSylvestre Marechaux, Delphine Corseaux, Andre Vincentelli, et al.
The American Journal of Cardiology|December 24, 2013
Prognostic usefulness of left ventricular hypertrophy by electrocardiography in patients with atrial fibrillation (from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study)Paolo Verdecchia, Gianpaolo Reboldi, Giuseppe Di Pasquale, et al.
Journal of the American College of Cardiology|July 18, 2018
Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial FibrillationAnthony P Kent, Martina Brueckmann, Mandy Fraessdorf, et al.
International Journal of Cardiology|June 21, 2015
Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trialMichela Brambatti, Harald Darius, Jonas Oldgren, et al.
Circulation|February 26, 2013
Response to letter regarding article, "Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a randomized evaluation of long-term anticoagulation therapy (RE-LY) substudy"Ziad Hijazi, Jonas Oldgren, Lars Wallentin, et al.
The American Journal of Cardiology|July 24, 2012
Detection of previously undiagnosed atrial fibrillation in patients with stroke risk factors and usefulness of continuous monitoring in primary stroke preventionPaul D Ziegler, Taya V Glotzer, Emile G Daoud, et al.
Pageof 19

Showing results (81-90 of 187) with videos related to

Sort By:
Pageof 19
Circulation|October 2, 2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarinAmmar Majeed, Hun-Gyu Hwang, Stuart J Connolly, et al.
International Journal of Cardiology. Heart & Vasculature|October 17, 2022
Retrospective Comparison of Patients ≥ 80 Years With Atrial Fibrillation Prescribed Either an FDA-Approved Reduced or Full Dose Direct-Acting Oral AnticoagulantRoy Taoutel, Michael D Ezekowitz, Usman A Chaudhry, et al.
Circulation|August 7, 2016
Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy)Michael D Ezekowitz, Rangadham Nagarakanti, Herbert Noack, et al.
American Heart Journal|April 15, 2018
Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysisZiad Hijazi, Stefan H Hohnloser, Jonas Oldgren, et al.
Cardiovascular Pathology : the Official Journal of the Society for Cardiovascular Pathology|April 12, 2008
Identification of tissue factor in experimental aortic valve sclerosisSylvestre Marechaux, Delphine Corseaux, Andre Vincentelli, et al.
The American Journal of Cardiology|December 24, 2013
Prognostic usefulness of left ventricular hypertrophy by electrocardiography in patients with atrial fibrillation (from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study)Paolo Verdecchia, Gianpaolo Reboldi, Giuseppe Di Pasquale, et al.
Journal of the American College of Cardiology|July 18, 2018
Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial FibrillationAnthony P Kent, Martina Brueckmann, Mandy Fraessdorf, et al.
International Journal of Cardiology|June 21, 2015
Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trialMichela Brambatti, Harald Darius, Jonas Oldgren, et al.
Circulation|February 26, 2013
Response to letter regarding article, "Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a randomized evaluation of long-term anticoagulation therapy (RE-LY) substudy"Ziad Hijazi, Jonas Oldgren, Lars Wallentin, et al.
The American Journal of Cardiology|July 24, 2012
Detection of previously undiagnosed atrial fibrillation in patients with stroke risk factors and usefulness of continuous monitoring in primary stroke preventionPaul D Ziegler, Taya V Glotzer, Emile G Daoud, et al.
Pageof 19